Goldman Sachs·2026-02-10 09:40Investment Rating - The report assigns a "Buy" rating to the company, believing its current stock price is undervalued due to a high implied weighted average cost of capital of 12% [1] Core Insights - The report highlights that the company, Innovent Biologics, is expected to maintain its leading position in the Chinese biotechnology sector, driven by a strong pipeline of novel molecules targeting next-generation immuno-oncology [1] - Encouraging preliminary data has been obtained for IBI363, a PD-1/IL-2α bispecific antibody, which exhibits differentiated drug characteristics in immunotherapy and cold tumors [1] - The company's robust commercialization capabilities and deep collaboration with global partners, particularly Eli Lilly, are also emphasized as key strengths [1] Summary by Relevant Sections - Investment Rating: "Buy" rating with a target price of HKD 102.85 based on risk-adjusted discounted cash flow [1] - Market Position: Innovent Biologics is positioned as a leader in the Chinese biotech field, supported by a strong pipeline and strategic partnerships [1] - Product Development: IBI363 shows promising initial results, indicating potential for differentiation in the competitive landscape of immunotherapy [1] - Commercialization Strength: The company’s strong commercial capabilities and partnerships enhance its market prospects [1]